The trial will include up to 24 participants aged between six months and 12 years with confirmed gain-of-function variants causing GRIN-related disorders. Credit: Ben Wicks on Unsplash.

GRIN Therapeutics has dosed the first participant in the Phase IB Honeycomb clinical trial of radiprodil to treat GRIN-related disorders.

The open-label trial has been designed for assessing the pharmacokinetics, tolerability, safety, and effects on seizures, sleep, and behavioural symptoms, as well as motor functions of several individually titrated radiprodil doses in the indicated children.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Up to 24 participants aged between six months and 12 years with confirmed gain-of-function (GoF) variants causing GRIN-related disorders, including variants on GRIN2A, GRIN2B, GRIN2D, and GRIN1, will be included in the trial.

The company stated that the trial will comprise a cohort of individuals who have experienced drug-resistant seizure frequency at least once weekly, and a cohort of patients with behavioural and other symptoms who have experienced fewer or no seizures.

A screening period, a titration period, and a maintenance period on the highest tolerated dose will be included in the trial.

See Also:

The study participants will have the option to enter a long-term extension study, after completion of the treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GRIN Therapeutics’ parent company Neurvati Neurosciences chief medical officer Michael Panzara said: “GRIN-related disorders represent a significant area of unmet need in healthcare, and the initiation of the Honeycomb Study is a historic milestone for GRIN Therapeutics and for patients around the world who are in desperate need of new treatments.

“We continue to be inspired by the children and families affected by GRIN-related disorders and by the leaders from the treatment community who have supported this important research and are very grateful for their partnership.”